Cedelizumab
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Cedelizumab is a monoclonal antibody acting on the immune system.[1] Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases.[2]
It has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC).[3]
Vedolizumab is a humanized monoclonal antibody, which binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7) on T lymphocytes to interfere with lymphocyte trafficking to the gut.[3]
References
- v
- t
- e
(initiation)
Antimetabolites |
|
---|---|
Macrolides/ other IL-2 inhibitors | |
IMiDs |
(reception)
IL-1 receptor antagonists | |
---|---|
mTOR |
Antibodies |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
-cept (Fusion) |
- Avacopan
- Baricitinib
- Bimekizumab
- Blisibimod
- Briakinumab
- Brodalumab
- Canakinumab
- Crovalimab
- Danicopan
- Darvadstrocel
- Deucravacitinib
- Deuruxolitinib
- Dimethyl fumarate
- Diroximel fumarate
- Efgartigimod alfa (+hyaluronidase)
- Etrasimod
- Filgotinib
- Fingolimod
- Guselkumab
- Iptacopan
- Itacitinib
- Ixekizumab
- Netakimab
- Olokizumab
- Ozanimod
- Peficitinib
- Pegcetacoplan
- Pirfenidone
- Ponesimod
- Ravulizumab
- Risankizumab
- Ritlecitinib
- Rozanolixizumab
- Sarilumab
- Satralizumab
- Siltuximab
- Siponimod
- Sirukumab
- Spesolimab
- Sutimlimab
- Tildrakizumab
- Tofacitinib
- Upadacitinib
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
![]() | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e